Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. In June 2021, the ACR released an updated guideline for the treatment of rheumatoid arthritis. The guideline underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Meanwhile, the most recent research in RA is explored by expert Jeffrey Curtis, MD, MS, MPH.
FEATURED ARTICLE: Patients with RA in the Setting of Cardiovascular Disease
Over the past decade, a number of pilot studies have provided proof of concept for the use of vagus nerve stimulation (VNS) to treat rheumatic conditions. The studies represent an expansion of this treatment approach into rheumatology, building on years of scientific inquiry into the mechanisms of VNS on disease states that led to preclinical…
Background & Objectives Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with immune responses to the patient’s own antigens and characterized by inflammation and substantial joint destruction. Prevotella copri, a gut commensal bacterium, has been reported to be an immune-relevant organism in individuals with RA. This study sought to evaluate antibody responses to anti-P….
Research by Chicre et al. found that Janus kinase inhibitors may significantly increase the risk of major adverse cardiac events and all-cause death in patients with rheumatoid arthritis (RA) when compared with other RA treatments. This study highlights the need for more comparative safety studies.
Despite an expanding armamentarium of disease-modifying treatments for rheumatoid arthritis (RA), some patients with RA remain symptomatic.1 Current treatment guidelines from both the ACR and the European Alliance of Associations for Rheumatology (EULAR) recommend treat-to-target strategies to achieve remission or low disease activity, and patients want to feel better.2,3 So how can we best help…
A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.
In early June, the ACR released an updated guideline on the management of rheumatoid arthritis, which includes new recommendations for specific high-risk groups.1 The guideline includes 44 recommendations—seven of which are strong and 37 conditional. It underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Guideline Development Process At…